The drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
- Moderna’s stock soared Tuesday after the COVID-19 vaccine maker detailed progress in developing a preventive shot for a deadly form of skin cancer.
“We are very excited, we are moving very quickly with Merck onto phase 3 for this study,” Moderna CEO Stephane Bancel told CNBC Tuesday morning. In a mid-stage clinical trial involving 157 patients, researchers compared the vaccine-Keytruda combination with Keytruda alone. The treatments continued for about a year in both groups unless the disease came back or side effects became too severe.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%A combination of Moderna Inc's melanoma vaccine and Merck & Co's immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.
Read more »
Experimental mRNA cancer vaccine with immunotherapy reduces risk of melanoma returning, preliminary study finds | CNNAn experimental personalized mRNA vaccine in combination with the immunotherapy Keytruda reduced the risk of recurrence or death from melanoma in patients who had already had surgery, Moderna and Merck said Tuesday.
Read more »
Merck, Moderna detail potential skin cancer vaccine progressMerck and Moderna said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had the tumors removed in surgery.
Read more »
Merck, Moderna share positive progress of potential skin cancer vaccineA potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said.
Read more »
Merck, Moderna share positive progress of potential skin cancer vaccineA potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said. FOX13
Read more »
Merck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Read more »